The board of directors of Everest Medicines Limited announced that Ms. Leah Liu has been appointed as the joint company secretary of the Company with effect from 28 March 2022. After the aforesaid appointment, the existing company secretary of the Company, Ms. Lau Yee Wa will continue to serve as the other joint company secretary. Ms. Liu joined the Company in October 2021 and is the vice president of corporate affairs of the Company, responsible for overseeing the compliance affairs in relations to capital markets, public relations, board of directors, and The Stock Exchange of Hong Kong Limited.

Prior to joining the Company, Ms. Liu was chief financial officer of Laekna Therapeutics and head of capital markets at I-Mab where she led financing and capital markets efforts, including listing preparations. Ms. Liu also worked in CloudMinds Technology (Hong Kong) Limited and Xtep International Holdings Limited as the head of capital markets and director of investor relations respectively and was the recipient of multiple industry awards. Ms. Liu has extensive experience in the financial services and investment industries and held positions at major international investment banks including The Hongkong and Shanghai Banking Corporation Limited, Daiwa Capital Markets Hong Kong Limited and Lazard Ltd.